Evidence map›Paper›PMID 31941156›Full record

ArticleMolecules (Basel, Switzerland)2020

Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-Raf-MEK-ERK Pathway.

Min-Hong Hsieh, Jia-Sin Yang, Renn-Chia Lin, Yi-Hsien Hsieh, Shun-Fa Yang, Horng-Rong Chang, Ko-Hsiu Lu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Anticancer activity of glycoalkaloids fromFrontiers in pharmacology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Min-Hong HsiehInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Jia-Sin YangInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Renn-Chia LinDepartment of Orthopedics, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
Yi-Hsien HsiehInstitute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan.
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Horng-Rong ChangInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Ko-Hsiu LuDepartment of Orthopedics, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
Chung Shan Medical University Hospital · TWChung Shan Medical University · TW

Funding

Chung Shan Medical University Hospital CSH-2019-D-002
6 · The paper itself

Abstract

Osteosarcoma, which is the most prevalent malignant bone tumor, is responsible for the great majority of bone cancer-associated deaths because of its highly metastatic potential. Although tomatidine is suggested to serve as a chemosensitizer in multidrug-resistant tumors, the anti-metastatic effect of tomatidine in osteosarcoma is still unknown. Here, we tested the hypothesis that tomatidine suppresses migration and invasion, features that are associated with metastatic process in human osteosarcoma cells and also investigate its underlying pathway. Tomatidine, up to 100 μM, without cytotoxicity, inhibited the invasion and migration capabilities of human osteosarcoma U2OS and HOS cells and repressed presenilin 1 (PS-1) expression of U2OS cells. After the knockdown of PS-1, U2OS and HOS cells' biological behaviors of cellular invasion and migratory potential were significantly reduced. While tomatidine significantly decreased the phosphorylation of c-Raf, mitogen/extracellular signal-regulated kinase (MEK), and extracellular signal-regulated protein kinase (ERK)1/2 in U2OS cells, no obvious influences on p-Jun N-terminal kinase, p38, and Akt, including their phosphorylation, were observed. In ERK 1 silencing U2 OS cells, tomatidine further enhanced the decrease of their migratory potential and invasive activities. We conclude that both PS-1 derived from U2OS and HOS cells and the c-Raf-MEK-ERK pathway contribute to cellular invasion and migration and tomatidine could inhibit the phenomenons. These findings indicate that tomatidine might be a potential candidate for anti-metastasis treatment of human osteosarcoma.

Indexed as

Bone NeoplasmsCell Line, TumorCell MovementExtracellular Signal-Regulated MAP KinasesHumansMAP Kinase Signaling SystemOsteosarcomaPresenilin-1Proto-Oncogene Proteins c-rafTomatineExtracellular Signal-Regulated MAP KinasesPresenilin-1Proto-Oncogene Proteins c-rafPSEN1 protein, humanRaf1 protein, humantomatidineTomatineERKmetastasisosteosarcomaPS-1tomatidine

Identifiers

PMID31941156
PMCPMC7024336
OpenAlexW2999452906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.